Hormones and Neurotransmitters Associated with Depression and Anxiety
Depression and anxiety are fundamentally linked to dysregulation of multiple neurotransmitter systems (serotonin, norepinephrine, dopamine, GABA, glutamate), neuropeptides (CRH, substance P, neuropeptide Y, vasopressin, galanin), the hypothalamic-pituitary-adrenal (HPA) axis with cortisol dysregulation, thyroid hormones (TSH, T3, T4), and the endocannabinoid system. 1, 2
Primary Neurotransmitter Systems
Monoamines
The classical monoaminergic hypothesis remains central to understanding both disorders:
- Serotonin (5-HT): Deficiency or receptor dysfunction is implicated in both depression and anxiety, forming the basis for SSRI efficacy 3, 1
- Norepinephrine: Dysregulation affects arousal, attention, and stress response in both conditions 3, 1
- Dopamine: Reduced dopaminergic activity particularly affects reward pathways and motivation in depression 1
- GABA: The primary inhibitory neurotransmitter; deficits contribute to anxiety symptoms 1
- Glutamate: Excitatory neurotransmitter imbalances affect neural plasticity and are increasingly recognized in both disorders 2
Neuropeptide Systems
Corticotropin-Releasing Hormone (CRH) is elevated in cerebrospinal fluid in both anxiety and depression, representing a shared pathophysiological feature 4, 5, 3. CRH acts primarily through CRH₁ receptors to produce anxiety- and depression-like symptoms. Clinical trials with CRH₁ receptor antagonists (NBI-30775/R121919) demonstrated antidepressant efficacy comparable to paroxetine 5.
Additional neuropeptides involved include 4:
- Substance P: Modulates monoaminergic transmission
- Neuropeptide Y: Anxiolytic properties
- Vasopressin: Stress response modulation
- Galanin: Affects mood regulation
HPA Axis and Cortisol: The Critical Distinction
A crucial difference exists between anxiety and depression in HPA axis function 3, 6:
In Depression:
- Hypercortisolemia (elevated cortisol)
- Non-suppression after dexamethasone administration
- Decreased glucocorticoid receptors
- Loss of hippocampal inhibition from repeated stress-induced damage 3
In Anxiety Disorders:
- Hypocortisolemia (reduced cortisol) 3
- Supersuppression after dexamethasone 3
- Increased glucocorticoid receptors 3
- Higher cortisol rhythm disorder incidence when anxiety complicates depression 7
In PTSD (distinct pattern):
This represents opposite failures in adaptive stress response, suggesting these disorders require differential therapeutic strategies despite symptom overlap 6.
Thyroid Hormone System
Significant comorbidity exists between anxiety disorders and thyroid dysfunction 9. The hypothalamic-pituitary-thyroid (HPT) axis shows:
- Blunted TSH responses to TRH stimulation in panic disorder and social anxiety disorder 9
- Inverse relationship between self-reported anxiety levels and TSH 9
- Thyroid hormone receptors in limbic system areas governing emotion 9
- Cross-communication between thyroid, noradrenergic, and serotonergic systems 9
Clinical implication: Routine thyroid screening is recommended in patients with anxiety disorders 9.
Endocannabinoid System
The endocannabinoid system (ECS) represents an emerging target 10:
- CB₁ receptor activation promotes hippocampal neurogenesis and synaptic plasticity
- Enhances BDNF (brain-derived neurotrophic factor) expression through cAMP and MAPK/ERK pathways 10
- ECS deficits associated with depressive/anxiogenic behaviors
- Conventional antidepressants (SSRIs, SNRIs, TCAs, bupropion) modulate ECS components 10
- Genetic polymorphisms in CB₁ receptor gene (CNR1) influence antidepressant efficacy 10
The Neuroendocrine Continuum Model
A proposed model suggests anxiety occurs first during the life course, with major depressive episodes developing later 3. This progression involves:
- Initial CRH elevation in both conditions
- General desensitization of CRF receptors at pituitary, limbic, and cortical levels
- Loss of hippocampal inhibition from repeated stress
- Transition from hypocortisolemia (anxiety) to hypercortisolemia (depression)
Clinical Significance
Normalization of HPA-system abnormalities is a strong predictor of clinical course in both major depression and panic disorder 8. The distinct hormonal profiles between anxiety and depression underscore why similar treatment approaches may not be optimal despite overlapping anxiety-depressive symptoms 6.
The integration of monoaminergic, neuropeptide, endocrine, and endocannabinoid systems provides multiple therapeutic targets beyond traditional monoamine-focused treatments, particularly relevant for treatment-resistant cases 10, 2.